Zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (

A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)

Disease Types: Solid Tumors

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Phase 2, open-label, multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)

For More Information:

https://clinicaltrials.gov/study/NCT06695845?term=%20JZP598-206&rank=1